Pulmonx reports Q4 EPS (25c), consensus (38c)

Reports Q4 revenue $22.6M, consensus $21.73M. “While our recent performance reflects a period of transition, we see a substantial opportunity to rebuild momentum through a clear operating plan focused on our highest-impact initiatives, including reaccelerating commercial growth and advancing our clinical pipeline,” said Glen French, President and Chief Executive Officer of Pulmonx (LUNG). “We have strengthened our balance sheet and are executing with increased focus and financial discipline to align investments with growth expectations to support a sustainable path to profitability.”